CA1 Responsiveness of the EQ-5D in Oncology: A Meta-Analysis  by Smith, A.B. et al.
VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6
Copyright © 2013, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.
Avai lable onl ine at www.sc iencedirect .com
journal homepage: www.elsevier .com/ locate / jva l
ISPOR 16TH ANNUAL EUROPEAN CONGRESS RESEARCH ABSTRACTS 
RESEARCH PODIUM PRESENTATIONS – SESSION I 
HEALTH CARE ExPENDITURE OR REIMBURSEMENT STUDIES – BIOLOGICS
BI1
ADHERENCE AND RESOURCE USE AMONG PATIENTS TREATED wITH 
BIOLOGICS. FINDINGS FROM THE BEETLE STUDy (BIOLOGICAL DRUGS: 
EvALUATION OF ECONOMICS, TREATMENTS, AND LABELING IN REAL-wORLD 
SETTING)
Degli Esposti L., Sangiorgi D., Buda S.
CliCon Srl, Ravenna, Italy
Objectives: Systemic administration of anti-TNF alpha leads to an anti-inflamma-
tory and joint protective effect in pathologies such as rheumatoid arthritis, psoriasis, 
Crohn’s disease. The aim of this study was to assess adherence to therapy and stay 
on treatment (no switches or interruptions) of patients treated with biologics accord-
ing to therapeutic indication and to calculate health care resources consumption 
(drugs, outpatient services, hospitalizations). MethOds: An observational retrospec-
tive cohort analysis based on 5 Local Health Units administrative databases was 
conducted. Patients who filled at least one prescription for anti-TNF alpha between 
January 1, 2009-December 31, 2011 were included. Patients were followed-up for one 
year. Patients were defined as adherent if they had > 80% of follow up period covered 
by drugs dispensation. Results: A total of 1219 patients were analyzed, 47% male, 
age 49.6±14.6. Patients affected by rheumatoid arthritis were 36%, psoriasis 31%, 
Crohn’s disease 10%, psoriatic arthritis 7%, ulcerative colitis 3%, ankylosing spon-
dylitis 3%, diagnosis not available 11%; 420 (34%) were treated with Adalimumab, 
615 (50%) Etanercept, 184 (15%) Infliximab. Among the 94% of patients who did not 
switch, patients treated with Infliximab seemed to have the highest rate of adherent 
patients across all indications: 51%, vs. 27% Etanercept and 23% Adalimumab; at the 
multivariable logistic regression model, Infliximab resulted a protective predictor 
of non adherence for all indications (OR ranged from 0.08 to 0.43). For patients who 
started a first-line biological drug, stay on treatment was 73% for Infliximab, 67% 
Etanercept, 64% Adalimumab. The mean annual expenditure for each patient in analy-
sis was € 11,120; in particular, non-pharmacological expenditure was € 988 for adherent 
and € 1,255 for non-adherent patients; at the multivariable generalized linear model, 
Infliximab was associated with the lowest cost for all indications. cOnclusiOns: 
Patients treated with Infliximab were associated to higher adherence and stay on 
treatment and lower costs, as compared to Adalimumab and Etanercept.
BI2
wHAT ARE THE KEy DRIvERS OF REIMBURSEMENT FOR BIOSIMILARS? AN 
ExAMINATION OF REIMBURSEMENT PROCESSES AND RECOMMENDATIONS 
ACROSS NINE COUNTRIES
de Silva S.U., Smith T.A., Bending M.W.
Mapi, London, UK
Objectives: Biosimilars are biotherapeutic products that are similar in terms of 
quality, safety and efficacy to an already licensed reference biotherapeutic product. 
The first biosimilar (Omnitrope) received EU regulatory approval in 2006; since then, 
14 biosimilars have received marketing authorisation. This study examined the dif-
ferences in the approaches to reimbursement of biosimilars in countries using HTA 
to inform decision-making. MethOds: Four biosimilar medicines were selected to 
provide sufficient documentation in seven European countries, South Korea and 
Australia. Regulatory approval and HTA reimbursement decision documents were 
identified and a qualitative analysis of the processes, recommendations by indica-
tion, evidence and key decision drivers was undertaken to explain differences in 
recommendations across countries. Results: Twenty-one different indications 
were appraised; 90% of appraisals were ‘recommended’, 9% ‘recommended with 
restrictions’, and 1% were ‘not recommended’. The Netherlands and Germany 
accepted ‘clinical comparability’ to the originator as sufficient evidence for auto-
matic reimbursement. Sweden and France were the only countries to appraise and 
to recommend for all indications. Scotland and Wales recommended all biosimilars 
but restricted indications in some cases. Agencies accepted the notion of clinical 
comparability and extrapolation across indications when appraising the evidence. A 
cost-minimisation analysis and budget impact analysis were key economic decision 
drivers. A full cost-effectiveness analysis was only requested by NICE. Other factors 
influential in recommending reimbursement were: lobbying, dual reimbursement 
processes, and other reimbursement mechanisms. cOnclusiOns: As the market 
for biosimilars continues to grow, it is imperative that specific HTA reimbursement 
processes are developed for assessing biosimilars. This includes further research 
on how different drug classes should be considered; especially pertinent due to the 
increase in biosimilars for monoclonal antibody-based drugs, which differ from the 
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product classes (erythropoietin, white blood cell stimulators, growth hormone and 
insulins) currently dominating the market.
BI3
DIFFERENCES IN APPROACH TO BIOSIMILARS: NICE vERSUS SMC 
RECOMMENDATIONS
Izmirlieva M., Ando G.
IHS, London, UK
Objectives: Several biosimilar products have been approved for marketing in the 
European Union, but their market penetration remains slow. Lack of clear reimburse-
ment guidance could be one of the reasons for this slow penetration. This study exam-
ines how many, if any, biosimilar products have been assessed in the UK by NICE and 
by the SMC and to what extent recommendations by the two HTA organisations are 
consistent. MethOds: Secondary research was conducted, including a review of all 
NICE and SMC final guidance and of guidance in progress by NICE to compare the HTA 
process outcome and issues raised by the two HTA agencies. Results: NICE has issued 
only one final guidance for a biosimilar product (Omnitrope) and has another guid-
ance in progress (for epoetin including biosimilars). The SMC has issued guidance for 
4 biosimilar versions of filgrastim (Ratiograstim, TevaGrastim, Zarzio and Nivestim), 
2 biosimilar versions of epoetin (Binocrit and Retacrit) and 1 version of somatropin 
(Omnitrope). All SMC guidance for biosimilars issued to date has been positive. The 
NICE guidance for Omnitrope is positive despite some reservations about the economic 
model. cOnclusiOns: Considering the limited overlap between NICE and SMC deci-
sions (only one drug - Omnitrope - was considered by both agencies), it is difficult to 
assess consistency in the SMC approach compared to NICE’s approach at this stage. 
Based on the biosimilars HTA guidance by NICE and the SMC to date, a cost-minimisa-
tion analysis may be acceptable for biosimilars even if such an approach - in the absence 
of a full cost-effectiveness model - might be rejected for an originator product. Both HTA 
agencies recommend that prescribing for biosimilars should be by brand name to avoid 
automatic substitution in the pharmacy.
BI4
IMPACT OF ExCLUSIvE HOSPITAL DISTRIBUTION OF BIOSIMILAR ON DRUG 
HEALTH CARE BUDGET
Rémuzat C.1, Vataire A.L.2, Cetinsoy L.2, Aballea S.1, Toumi M.3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, PARIS, France, 3University Claude Bernard  
Lyon 1, Lyon, France
Objectives: There is an increased trend in shifting biologics distribution to exclu-
sive hospital pharmacy channel. Although it looks obvious that such process will 
generate savings through tenders at regional or national level such policy conse-
quences were not clearly quantified. We used a model developed for EU commission 
to assess the consequences of such policies on biosimilars for selected EU countries 
(model developed for the European Commission for the project”EU Pharmaceutical 
expenditure forecast” http://ec.europa.eu/health/healthcare/key_documents/index.
en.htm). MethOds: We built a model to assess policy scenarios impact on pharma-
ceuticals reference forecast for seven EU Member States (France, the UK, Germany, 
Poland, Portugal, Greece and Hungary). We tested the impact of shifting biosimilar 
distribution to hospital channel on pharmaceutical industry revenue, Health insurers 
budget and society cost. Results: For the period 2012-2016 the savings of biosimilars 
(based in million Euros) for Health insurance will be for: UK 2,023; GE 1,127; FR 1,634; PL 
200; GR 19; PO 272; HU 29. The extra savings by shifting of the biosimilars distribution 
to exclusive hospital pharmacy will be: for UK 353; GE 3,392; FR 1,684; PL 37; GR 206; PO 
65; HU 176. The difference is relatively small for UK, although significant. However, it is 
considerable for Germany and France (around 3 and 2 time original saving). Similar fig-
ures (revenue loss) are seen for pharmaceutical companies. cOnclusiOns: Although 
the impact of such policy varies from one country to one another based on initial pro-
portion of biosimilar distributed through hospital and level of discount over branded 
products, this policy appears to have a substantial impact on drug expenditures and 
might contribute to sustainability of health insurance in EU countries. Germany and 
France might benefit dramatically from such policy.
CANCER OUTCOMES RESEARCH STUDIES
CA1
RESPONSIvENESS OF THE EQ-5D IN ONCOLOGy: A META-ANALySIS
Smith A.B.1, Cocks K.1, Taylor M.2, Parry D.3
1University of York, York, UK, 2York Health Economics Consortium, York, UK, 3AstraZeneca UK, 
Macclesfield, UK
Objectives: The EQ-5D is often employed in clinical trials to derive quality-
adjusted life years for cost-utility analyses, and in comparisons of health-related 
quality of life across conditions. However, there are concerns that the EQ-5D is less 
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Objectives: To assess the economic burden of cancer by estimating years of poten-
tial productive life lost (YPPLL) and costs of lost productivity due to premature can-
cer-related mortality across Europe. MethOds: We derived the number of cancer 
deaths by sex for 23 of the most common cancer sites in 30 European countries from 
GLOBOCAN. YPPLL were calculated by multiplying the number of cancer-specific 
deaths for each productive age group (15-64) by standard life expectancy at the 
mid-point for each age group. Using the human capital approach, we multiplied 
standardised YPPLL for each individual by country- age- and gender-specific annual 
wages from age of death until retirement following adjustments for labour force 
participation and unemployment. Costs were expressed in 2008€ . Results: All 
cancer sites combined generated a total of € 150.9 billion in premature mortality 
costs in Europe in 2008. Western Europe accounted for almost half of the total, 
followed by Northern (21%), Southern (21%) and Central & Eastern Europe (9%). 
Findings contrasted with YPPLL where Central & Eastern Europe had the highest 
burden. Male costs exceeded female costs by 88% in Europe as a whole (male: € 98.4 
billion; female: € 52.5 billion) and across all European regions. Lung was the most 
expensive site (€ 34.7 billion; 23% of total costs), followed by breast cancer (€ 13.6 
billion, 9%), colorectal cancer (€ 12.1 billion, 8%), brain & CNS (€ 9.1 billion, 6%) and 
pancreatic cancer (€ 7.5 billion, 5%). According to premature mortality cost per death, 
testicular cancer was the most expensive site (€ 2.5 million per death), followed by 
brain & CNS cancer (€ 481,512) and Hodgkin lymphoma (€ 474,559). cOnclusiOns: 
Lost productivity costs due to cancer-related premature mortality are significant in 
Europe. Productivity costs provide an alternative perspective on the cancer burden 
on society and may inform cancer control policy decisions.
CONCEPTUAL PAPERS
CP1
INCREMENTAL COST PER QUALITy-ADjUSTED LIFE yEAR GAINED? THE NEED 
FOR ALTERNATIvE METHODS TO EvALUATE MEDICAL INTERvENTIONS FOR 
ULTRA-RARE DISORDERS
Schlander M.1, Garattini S.2, Kolominsky-Rabas P.3, Nord E.4, Persson U.5, Postma M.6, 
Richardson J.7, Simoens S.8, Sola Morales O.9, Tolley K.10, Toumi M.11
1University of Heidelberg, Wiesbaden, Germany, 2Mario Negri Institute for Pharmacological 
Research, Milano, Italy, 3University of Erlangen-Nuremberg, Erlangen, Germany, 4Norwegian 
Institute of Public Health, Oslo, Norway, 5The Swedish Institute for Health Economics, Lund, 
Sweden, 6Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, 
University of Groningen, Groningen, The Netherlands, 7Monash University, Melbourne, Australia, 
8KU Leuven, Leuven, Belgium, 9HITT, Barcelona, Spain, 10Tolley Health Economics, Buxton, UK, 
11University Claude Bernard Lyon 1, Lyon, France
Objectives: To critically appraise the problems posed by the systematic valua-
tion of interventions for ultra-rare disorders using conventional health economic 
analysis methods. MethOds: An international group of clinical and health eco-
nomic experts met in conjunction with the Annual European ISPOR Congress in 
Berlin/Germany, November 2012, to identify and deliberate underlying issues openly, 
adhering to the Chatham House rule. Results: The group reached a broad consen-
sus, including: The complexities of research and development new treatments for 
ultra-rare disorders (URDs) may require conditional approval and reimbursement 
policies, such as coverage with evidence development agreements, but should not 
be used as a justification for showing surrogate endpoint improvement only. As a 
prerequisite for value assessment, demonstration of a minimum significant clinical 
benefit should be expected within a reasonable timeframe. Regarding the economic 
evaluation of interventions for URDs, the currently prevailing logic of cost effective-
ness (using benchmarks for the maximum allowable incremental cost per quality-
adjusted year, QALY, gained) was considered inappropriate since it does not capture 
well-established social preferences regarding health care resource allocation. Such 
social preferences include, but are not limited to, a priority for care for the worse of 
(related to initial health state), for those with more urgent conditions (the so called 
“rule of rescue”), a relatively lower priority based upon capacity to benefit, and a 
dislike against “all or nothing” resource allocation decisions that might deprive 
certain groups of patients from any chance to access effective care. cOnclusiOns: 
Alternative paradigms to establish the “value for money” conferred by interventions 
for URDs should be developed with high priority. Such methods should capture and 
reflect prominent societal value judgments, beyond efficiency as conventionally 
defined by QALY maximization under a budget constraint.
CP2
THE MULTIMODEL ENSEMBLE APPROACH TO REDUCING STRUCTURAL 
UNCERTAINTy IN DECISION ANALyTICAL MODELLING
Parham P.E.1, Hughes D.A.2
1Bangor University, Gwynedd, UK, 2Bangor University, Bangor, UK
Decision analytical modelling represents an essential tool for undertaking health 
economic evaluation. Markov models provide a mathematical framework for such 
analyses, particularly in the context of assessing the cost-effectiveness of treat-
ments for chronic diseases where economic outcomes are typically extrapolated 
beyond the duration of clinical trials. However, structural uncertainty is a key chal-
lenge, to methodologists and decision makers alike, that has hitherto attracted 
insufficient attention. Best practice guidelines advocate the testing of structural 
assumptions through alternative modelling approaches or conducting scenario 
analyses. It should be recognised, however, that structural differences in model 
design represent a strength, rather than limitation, of the modelling process and 
in fields such as climate modelling, multi-model comparisons and ensemble pre-
dictions have been used extensively as the basis for more robust policy decisions. 
Methods for combining models represents an emerging field in climate modelling, 
but the simplest approach is to treat all models equally and the mean of all model 
predictions has been shown to improve on the ‘best’ model predictions in numerous 
studies. A weighted multi-model approach may also be developed, but this remains 
an area of ongoing debate. To date, health economists have not fully embraced the 
potential of the multi-model paradigm to reduce structural uncertainty. In this work, 
responsive to change particularly in oncology. Therefore the objective of this study 
was to determine the level of responsiveness of the EQ-5D in oncology. MethOds: 
A systematic review identified relevant articles reviewing responsiveness of the 
EQ-5D in adults (EMBASE, Medline). Effects sizes (ES) were calculated for the studies 
identified where not already reported. A meta-analysis was undertaken of the effect 
sizes: homogeneity of variance was assessed (fixed effects) and random effects 
models applied where there was significant heterogeneity. Responsiveness was also 
compared for improvement/deterioration in health status. Analyses were conducted 
in SPSS v18. Results: Data were available from 12 studies (3 breast, 2 prostate, as 
well as ovarian, lung and renal cancers) each with EQ-5D data at a minimum of 2 
time points leading to a total of 45 entries. The overall unweighted ES was -0.26 
(95%CI: -0.31 to -0.21), however there was significant heterogeneity in terms of effect 
sizes (Q(44) = 427.00, p< 0.001) which was accounted for using the random effects 
model (Q(44) = 39.58, p> 0.05). The overall weighted effect size (ES) was -0.17 (95%CI: 
-0.33 to -0.01). The weighted ES for improvement was 0.08 (95%CI: -0.02 to 0.18), and 
-0.52 (95%CI: -0.64 to -0.41) for deterioration. cOnclusiOns: There is considerable 
heterogeneity in the reported effect size of the EQ-5D. Responsiveness of the EQ-5D 
in oncology trials as measured by effect sizes is modest at best. The instrument 
appears to be more sensitive to deterioration in health status than to improvements. 
Further work will explore the ES of the EQ-5d in comparison with responsiveness 
of disease-specific measures and changes in health status.
CA2
THE BURDEN OF CAREGIvING IN CANCER: THE STATUS OF CLINICAL RESEARCH
Foster R.E., Bardos J.I., Wilson T.J., Hamerslag L., Kusel J.
Costello Medical Consulting Ltd., Cambridge, UK
Objectives: The responsibility of caring for cancer patients, often suffering from a 
magnitude of health problems, can result in a considerable burden for their caregiv-
ers, both physically and psychologically. The objective of this study was to assess 
the status and extent of clinical research into the burden of caregiving for cancer 
patients. MethOds: ClinicalTrials.gov was searched for all cancer trials that con-
sidered caregiver burden, using a matrix of search terms such as ‘carer’, ‘burden of 
care’ or ‘caregiver’. The impact of geographical location or cancer type on the pro-
portion of trials assessing caregiver burden, the outcome measures used and the 
proportion of trials including caregiver burden as an outcome over time were inves-
tigated. Results: From a total of 36,184 cancer-focused trials documented world-
wide, 1,596 (4%) assessed caregiver burden. Outcome measures included caregiver 
quality of life (QoL), satisfaction with care and mood states. The impact of caregiver 
burden in cancer trials within different world regions varied, with the highest pro-
portion of trials that considered caregiver burden located in Mexico (23%) and Asia 
(14-22%). Trials for five major cancer types (breast, lung, prostate, colorectal, liver) 
assessed caregiver burden at similar frequency (4-5%). Evaluation of completed tri-
als demonstrated that the proportion of cancer trials considering caregiver burden 
increased from < 1% between 1997-2001 to 7% after 2012. cOnclusiOns: Fewer 
than 5% of all cancer trials documented worldwide have evaluated the impact of 
caregiver burden, although geographical variation does exist. The equal assess-
ment of caregiver burden across cancer types may suggest that no single cancer 
type is considered to have a higher degree of caregiver burden. Interestingly, while 
the number of total cancer trials evaluating caregiver burden documented to date 
is relatively low, the incidence has increased over the last 15 years, suggesting that 
the growing importance of caregiver burden is being recognised.
CA3
EMA APPROvAL OF DRUGS ON THE BASIS OF PIvOTAL NON-COMPARATIvE 
PHASE II TRIAL DATA
Macaulay R.
HERON Health, London, UK
Objectives: The recent European Medicines Agency (EMA) approval of crizotinib has 
highlighted the potential for regulatory approval to be gained on the basis of pivotal non-
comparative Phase II data. This research aims to determine the circumstances under 
which the EMA will approve submissions on this basis. MethOds: All publicly available 
European Public Assessment Reports (EPARs) were screened up to June 2013. Submissions 
that were based on pivotal Phase II data were identified and the acceptance decision, 
disease, and level of benefit were extracted. Results: Eight drugs (bevacizumab, bort-
ezomib, crizotinib, dasatinib, everolimus, gefitinib, imatinib, ofatumumab) across ten 
indications been submitted to the EMA on the basis of pivotal non-comparative Phase II 
data. All submissions were for entry indications except imatinib, which was also submit-
ted for two further indications on this basis. All, except crizotinib, were for indications 
with no alternative therapies and all were for onology indications except everolimus 
which was for subependymal giant cell astrocytoma (SEGA). All, except crizotinib, were 
EMA designated orphan medical products for these indications. One submission was 
rejected (bevacizumab), one was restricted (ofatumumab), and eight were approved. 
Top-line supportive Phase III data was only available in two submissions (crizotinib and 
everolimus). Overall response rates (ORRs) were the primary endpoints in all submis-
sions except imantinib and dasatinib in leukaemia indications and everolimus in SEGA. 
Rejected drugs had ORRs of 47% (ofatumumab, rejected subpopulation) and 38% (beva-
cizumab). Approved drugs had ORRs of 60% (crizotinib), 58% (ofatumumab, approved 
subpopulation), 40% (imatinib), and 35% (bortezomib). Despite low ORRs, imatinib was 
used to treat a disease with no licensed therapies (gastrointestinal stromal tumours), 
and bortezomib offered a 10% complete remission rate. cOnclusiOns: Pivotal Phase II 
data can support EMA approval if it demonstrates substantial clinical benefits for small 
patient populations with severe diseases that lack therapeutic alternatives.
CA4
MEASURING THE COST OF LOST PRODUCTIvITy DUE TO PREMATURE CANCER-
RELATED MORTALITy: A EUROPEAN OvERvIEw
Hanly P.1, Soerjomataram I.2, Sharp L.3
1National College of Ireland, Dublin, Ireland, 2International Agency for Research on Cancer, Lyon, 
Ireland, 3National Cancer Registry Ireland, Cork, Ireland
